$2.600
-0.151 (-5.80%)Zum Schluss
BLRX-News
BLRX-Events
BioLineRx Reports Q2 Revenue of $294,000
Reports Q2 revenue $294,000 vs $304,000 last year. As of June 30, 2026, the Company had cash, cash equivalents, and short-term bank deposits of $13.1M. "During the second quarter and subsequent period, we advanced GLIX1 across multiple fronts," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Our Phase 1/2a study in glioblastoma is advancing as planned, with the second cohort in the Phase 1 part now being dosed, and the third cohort expected to commence dosing in September. To date, a little more than four months into the study, we have been very pleased with the drug's safety and tolerability."
BioLineRx Issues 1,348,921 ADS at $2.78 Each
BioLineRx announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the company's American Depositary Shares at a purchase price of $2.78 per ADS through a registered direct offering. In addition, the company has agreed to issue accompanying warrants to purchase up to an aggregate of 2,023,382 ADSs, at a purchase price of $2.78 per ADS via a concurrent private placement. The warrants will have an exercise price of $2.78 per ADS and will expire five years from the issuance date. Each ADS represents six hundred ordinary shares, par value NIS 0.10 per share, of BioLineRx. The closing of the offering is expected to occur on or about August 31. Chardan is acting as the exclusive placement agent for the offering.
BioLineRx Announces New Data on GLIX1 and PARP Inhibitors Synergy
BioLineRx announced new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft model of ovarian cancer. Today's results represent a "compelling" in vivo confirmation of GLIX1 and PARPi synergy from an HR-proficient ovarian cancer PDX model: The study included six arms: cisplatin, GLIX1 monotherapy and olaparib monotherapy, low-dose GLIX1, a low-dose GLIX1/olaparib combination arm, and a control arm; Results show substantially better efficacy in the combination arm versus the control arm and versus the monotherapy arms, despite using lower doses in the combination arm; The low-dose GLIX1/olaparib combination tumor reduction was similar to cisplatin, the current chemotherapy benchmark
Company Reports Q1 Revenue of $0.5M, Achieves Milestone in GLIX1 Clinical Trial
Reports Q1 revenue $0.5M vs.$0.3M last year. "Since our last quarterly update, we achieved a significant milestone for our company and for the GLIX1 development program with the dosing of the first patient in our Phase 1/2a clinical trial of GLIX1 in glioblastoma," stated CEO Philip Serlin. "We are also very encouraged by compelling new pre-clinical data showing that GLIX1 demonstrated robust dose-dependent tumor-growth inhibition and survival benefit in orthotopic cell-derived xenograft GBM models. Furthermore, in a newly completed subcutaneous TMZ-resistant patient-derived xenograft GBM model, GLIX1 demonstrated a robust anti-tumor effect while no effect was observed with TMZ, highlighting the potential to address the very high unmet need in GBM. In the coming days, we look forward to engaging with the broader oncology community at this year's ASCO meeting with two abstracts featuring GLIX1..."
BioLineRx and Hemispherian Release Encouraging Preclinical Data for GLIX1
BioLineRx and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for the treatment of recurrent and progressive GBM and other high-grade gliomas. GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment. In a comprehensive pre-clinical program, orally administered GLIX1 demonstrated robust anti-tumor activity in orthotopic cell-derived xenograft GBM models, as well as in a newly completed subcutaneous TMZ-resistant patient-derived xenograft GBM model. In the three orthotopic CDX studies, significant tumor growth inhibition and survival benefit were observed following treatment with GLIX1 across all doses tested, with greater benefit at higher dose levels. In these models, mice treated with TMZ also showed significantly decreased tumor volume and survival benefit. Most notably, in the subcutaneous PDX model, GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect. BioLineRx and Hemispherian plan to present the data from these studies at one or more future medical conferences.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.